Randomized comparison of venlafaxine with escitalopram for selecting the antidepressant indicating better responses to serotonin-noradrenaline reuptake inhibitor(SNRI) or selective serotonin reuptake inhibitor(SSRI) for major depressive disorder(MDD)

Randomized comparison of venlafaxine with escitalopram for selecting the antidepressant indicating better responses to serotonin-noradrenaline reuptake inhibitor(SNRI) or selective serotonin reuptake inhibitor(SSRI) for major depressive disorder(MDD) - Selecting the better antidepressant from SNRI or SSRI for MDD; SENSE-study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022267

Enrollment

100

Registered

2016-06-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Cases starting venlafaxine for MDD episode or switching to venlafaxine from other antidepressants. Cases starting escitalopram for MDD episode or switching to venlafaxine from other antidepressants.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A) Major depressive episodes were diagnosed using the Structured Clinical interview for the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) B) The patients who were administered any antidepressants or those with no response to adequate amount of antidepressants (except for venlafaxine and escitalopram) for 4 weeks or more in the current episode. C) The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD17). The patients whose HAMD17 scores were 15 or above were enrolled in this study. D) The patients who can be signed informed concent were enrolled in the present study.

Exclusion criteria

Exclusion criteria: A) The patients who have any history of neurological diseases or other physical diseases. B) The patients who have comorbidities with other disorders, bipolar disorder, personality disorders, or mental retardation. C) The patients who have previous history of substance-related disorders, such as drug dependence or alcohol dependence. D) The patients who had previously treated with venlafaxine or escitalopram. E) The patients who their physicians consider not suited.

Design outcomes

Primary

Measure	Time frame
17-item Hamilton Rating Scale for Depression: HAMD17	—

Secondary

Measure	Time frame
Clinical Global Improvement-Severity (CGI-S) Quick Inventory of Depressive Symptomatology (QIDS-J) Udvalg for Kliniske Undersogelser (UKU) Cognitive function test (COGNITRAX)	—

Countries

Japan

Contacts

Public ContactShinsuke Hamada

University of Occupational and Environmental Health Department of psychiatry

now_to_last@yahoo.co.jp+81-936917253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026